Analyst Increases Q1 EPS Forecast for Sagimet Biosciences

Sagimet Biosciences Inc. (NASDAQ:SGMT) has seen an upgrade in its earnings per share (EPS) estimates for the first quarter of 2025. This change was announced in a research note from HC Wainwright on March 13th, 2025.

HC Wainwright analyst E. Arce now anticipates that Sagimet will report earnings of ($1.00) per share for the first quarter, an improvement from the earlier forecast of ($1.08). The firm maintains a “Buy” rating on the stock, along with a $32.00 price target, suggesting a positive outlook for the company in the future.

For the current fiscal year, analysts have a consensus estimate of ($1.60) in earnings per share for Sagimet Biosciences. In addition, HC Wainwright provided further estimates for the full year, predicting quarterly earnings of ($1.22) for Q2 2025, ($1.31) for Q3, and ($1.34) for Q4, leading to a total estimated loss of ($4.86) for FY2025. Looking further ahead, projections for FY2026 are ($5.77), FY2027 at ($5.44), FY2028 at ($3.74), and FY2029 at ($2.29).

Recently, on March 12th, Sagimet Biosciences reported its earnings, posting ($0.50) per share for the quarter, which was better than the consensus forecast of ($0.65) by $0.15, showcasing some financial improvement.

In other developments, Oppenheimer started coverage on Sagimet Biosciences on December 6th, giving it an “outperform” rating with a price target of $30.00. Presently, one analyst rates the stock as a hold, while six others give it a buy rating. Data from MarketBeat.com indicates that the stock has a consensus rating of “Moderate Buy” with a target price of $23.00.

Sagimet Biosciences Stock Performance

As of Monday, March 18th, 2025, Sagimet Biosciences traded at $3.78, reflecting a 1.1% increase. The company's market capitalization stands at approximately $115.95 million, reporting a PE ratio of -2.64 and a beta of 2.57. Over the last year, the stock has ranged between a low of $2.39 and a high of $7.38. Currently, its 50-day and 200-day moving averages are at $4.22 and $4.47, respectively.

Changes in Institutional Holdings

Recent trading activity shows notable changes among institutional investors regarding Sagimet Biosciences stock. Wells Fargo & Company MN acquired a new stake valued at $31,000 in the fourth quarter. Similarly, Jacksonville Wealth Management LLC and Summit Financial Wealth Advisors LLC have added shares, investing approximately $45,000 and $61,000, respectively. Overall, institutional investors and hedge funds hold about 87.86% of the stock.

About Sagimet Biosciences

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company based in the United States. The firm is focused on developing innovative therapeutics known as fatty acid synthase (FASN) inhibitors, targeting diseases caused by dysfunctional metabolic pathways. Its leading drug candidate, Denifanstat, is a selective FASN inhibitor designed for treating metabolic dysfunction associated with steatohepatitis.

In conclusion, Sagimet Biosciences is positioned for potential growth, as indicated by recent analyst upgrades and improving earnings performance. Investors may want to keep a close watch on the stock as it navigates through the upcoming quarters.

Sagimet, Biosciences, EPS, Forecast, Analyst